Financing of 1.3 Billion Yen was completed, allowing the conduction of POC clinical trials of CYT001
- Financing of 1.3 Billion Yen (around US$ 12 Million at current rate) was completed, through the achievement of the milestones, including the first IND filing of CYT001, pursuant to the agreement with current shareholders; i.e., NEC Corporation, NEC Capital Solutions Limited, Fast Track Initiative, Inc., and SMBC Venture Capital Co., Ltd.. In total, 2.3 Billion Yen (around US$ 21 Million) was raised from the establishment of Cytlimic in December 2016.
- In recent years, Immune-Checkpoint Inhibitors (ICI), such as anti-PD-(L)1 drug, have been expanding their applications; however, a combination of ICI with other drugs are still needed for more than 70% of patients who don’t respond to ICI alone. Among those combination drugs, cancer vaccine is considered as a promising approach to turn “Cold tumors to Hot ones” and to make ICI work.
- CYT001 is designed to effectively tern “Cold tumors to Hot ones” with the AI-designed optimized shared-antigen peptides, and an optimized combination adjuvant of Poly ICLC (Hiltonol) and LAG-3Ig (Eftilagimod alpha or IMP321). The resent financing allows Cytlimic to conduct further clinical trials for the POC establishment of CYT001.